Literature DB >> 3295117

Processing of MPTP by monoamine oxidases: implications for molecular toxicology.

A J Trevor, T P Singer, R R Ramsay, N Castagnoli.   

Abstract

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a selective nigrostriatal neurotoxin, is bioactivated by MAO-B (and less effectively by MAO-A) to 2,3-MPDP+ and this intermediate undergoes further oxidation to MPP+, partly through the activity of MAO forms. MPTP and its two primary metabolites are competitive inhibitors of both A and B forms of MAO. MPTP and 2,3-MPDP+ are also mechanism-based inactivators of both forms of the enzyme. A catalytic mechanism, involving the formation of radical intermediates, is proposed for the MAO-mediated oxidation of MPTP. Post-oxidation biochemical sequelae, possibly involved in the expression of neurotoxicity, include the active accumulation of MPP+ via dopamine reuptake systems, the energy-driven uptake of MPP+ by mitochondria and the inhibition of NADH dehydrogenase by pyridine derivatives. A scheme linking these events as steps in the molecular mechanism of action of MPTP is proposed and discussed in terms of the selective toxicity of the neurotoxin towards nigrostriatal cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3295117     DOI: 10.1007/978-3-7091-8901-6_5

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  6 in total

1.  Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  S M Efange; R J Boudreau
Journal:  J Comput Aided Mol Des       Date:  1991-10       Impact factor: 3.686

2.  Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse model.

Authors:  Xu Zhang; Jian-Ying Zhou; Mark H Chin; Athena A Schepmoes; Vladislav A Petyuk; Karl K Weitz; Brianne O Petritis; Matthew E Monroe; David G Camp; Stephen A Wood; William P Melega; Diana J Bigelow; Desmond J Smith; Wei-Jun Qian; Richard D Smith
Journal:  J Proteome Res       Date:  2010-03-05       Impact factor: 4.466

3.  The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice.

Authors:  Niharika Amireddy; Srinivas N Puttapaka; Ravali L Vinnakota; Halley G Ravuri; Swaroop Thonda; Shasi V Kalivendi
Journal:  J Biol Chem       Date:  2017-08-10       Impact factor: 5.157

Review 4.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

5.  Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice.

Authors:  M Gupta; H L Wiener
Journal:  Neurochem Res       Date:  1995-04       Impact factor: 3.996

6.  Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

Authors:  Giuseppe Battaglia; Carla L Busceti; Gemma Molinaro; Francesca Biagioni; Marianna Storto; Francesco Fornai; Ferdinando Nicoletti; Valeria Bruno
Journal:  J Neurosci       Date:  2004-01-28       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.